Convalescent plasma in patients receiving Rituximab or Ocrelizumab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder with COVID-19: A Multicenter Retrospective Study.
Dequidt T, Richier Q, Louapre C, Ader F, Merad Y, Lauwerier N, Jacomet C, Carles M, Biron C, Gendrin V, Marlat C, Danion F, Lepage TM, Sotto A, Bourdellon L, Mania A, Martinot M, Falher GL, Ferre A, Pilmis B, Gondran G, Simeone P, Henry M, Kamel T, Ray S, Ancellin S, Mélé N, Camou F, Destremau M, Sellenet J, Zucman N, Marechal ML, Mellouki K, Langlois ME, Paz DL, Mousset M, Leclerc C, Sommet A, Lacombe K, Martin-Blondel G.
Dequidt T, et al. Among authors: lacombe k.
Int J Infect Dis. 2024 Dec 4:107323. doi: 10.1016/j.ijid.2024.107323. Online ahead of print.
Int J Infect Dis. 2024.
PMID: 39643155
Free article.